Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Generic Market to Grow 9.4% in FY2015: Yano Research
June 18, 2015
- Japanese Generic Market to Reach 867.9 Billion Yen in FY2014: Survey
June 17, 2015
- Taiho Licenses Lonsurf to Servier of France for Europe
June 16, 2015
- Takeda to Submit Plans to Improve Business Operations after MHLW Order
June 15, 2015
- Lenvima More Beneficial to Patients against Sorafenib: Dr Tahara of National Cancer Center
June 15, 2015
- Carna Biosciences Licenses Its Kinase Inhibitor to Janssen Biotech of US
June 15, 2015
- Toujeo Shows Similar Glycemic Control to Lantus in PIII Study in Japanese Patients: Sanofi
June 12, 2015
- PeptiDream to Receive Milestone Payments from BMS for Designating Clinical Candidate Compound
June 12, 2015
- FY2014 Earnings of 24 Major Japanese Drug Makers: Jiho Tally
June 12, 2015
- NanoCarrier to Initiate PI Study of NC-6004 for Head, Neck Cancer in Japan
June 11, 2015
- Novartis Has High Hopes for T-Cell Therapy CTL019
June 10, 2015
- Novartis Japan Chief Vows All-Out Effort to Regain Trust
June 10, 2015
- No Difference from Clinical Trials in Incidence of Adverse Reactions to SGLT-2 Inhibitor: Prof. Kaku of Kawasaki Medical School
June 10, 2015
- R-Tech Ueno Partners with Autonomous University of Barcelona in Research for Development of VAP-1 Inhibitor
June 10, 2015
- Highlights of FY2014 Earnings - Part 5: Lackluster 1% Sales Growth Likely in FY2015
June 10, 2015
- Ethical Drug Sales Up 6.9% in April: Crecon Report
June 9, 2015
- Nesina Similar to Placebo in CV Event Risk in Patients on ACE Inhibitors: Takeda
June 9, 2015
- Once-Weekly Omarigliptin Reduces HbA1c Levels as Add-on Treatment in PIII Study in Japanese Patents: MSD
June 9, 2015
- Highlights of FY2014 Earnings - Part 4: Overseas Sales Top 4 Trillion Yen; Fate of Drug Makers Will Depend on New Global Products
June 9, 2015
- Highlights of FY2014 Earnings - Part 3: New Cancer Drugs Off to Strong Start
June 8, 2015
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…